Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices
Irvine, CA — October 6, 2021 – Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (OTCQB: KNWN), an emerging leader in noninvasive medical diagnostics, today published a new report on its non-invasive platform technology, Bio-RFIDTM, comparing its clinical accuracy to FDA-cleared glucose monitoring devices that are currently available in the market.
For these latest tests, human subjects placed their arms on a Bio-RFID sensor and their blood glucose levels were measured every five minutes over a period of two hours. Concurrent readings were taken with an Accu-Chek® fingerstick device and with two continuous glucose monitoring devices, Abbott FreeStyle® Libre and Dexcom G6®, which allowed the calculation of Bio-RFID’s MARD (mean absolute relative difference). MARD is the most common metric used to assess the performance of glucose monitoring systems, with a low percentage indicating the glucose readings are close to the reference glucose value, validating the device’s accuracy. Values under 10% are regarded to have good analytical performance. The Bio-RFID average MARD was between 5.3% and 6.7% when compared with the FDA-approved devices used in the study, which confirms that Bio-RFID can offer the high-level of clinical accuracy required by medical diagnostics devices.
“The accuracy achieved by Bio-RFID showcased in this report is supported by the hundreds of tests that our research and development team has conducted in the last few years and the continued optimization of our AI-powered algorithm. I couldn’t be prouder of the work done by our team,” said Phil Bosua, Know Labs CEO and Bio-RFID inventor. “This data confirms that Know Labs’ family of products can be an accurate, cost-effective and non-invasive alternative to the current FDA-cleared glucose monitoring devices in the market, and to the painful, inconvenient fingersticks still used by many millions of people with diabetes.”
Know Labs also published a video from its research and development laboratory that documents the internal tests and shows the progress made to miniaturize the Bio-RFID sensor, going from a 3 foot by 3 foot circuit board to a small device that fits in your pocket. The Bio-RFID sensor is the core component of Know Labs’ KnowU™ and UBand™, two non-invasive glucose monitoring devices that will address different market segments. KnowU offers on-demand and on-the-go use while the UBand addresses the continuous and wearable need.
“Our miniaturization efforts combined with our powerful predictive diagnostics AI brings us much closer to market,” said Ron Erickson, Know Labs Chairman and Founder. “Right now, we are focused on getting our human testing protocol approved by an independent review board so we can begin internal clinical studies.”
Know Labs is focused on launching what the company believes will be the world’s first noninvasive medical-grade glucose monitoring solution. As we progress toward that goal, updates will be provided. Additional details on Know Labs’ product portfolio, as well as copies of the report and the video mentioned above are available at www.knowlabs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.
About Boustead Securities, LLC
Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com
Form CRS/Reg BI Disclaimer:
Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing, LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.
Cautionary Statement Concerning Forward-Looking Statements
This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.